20/20 Genesystems Inc.

05/20/2025 | Press release | Distributed by Public on 05/20/2025 13:17

Annual Report by Private Issuer (Form C-AR)

FORM C UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
OMB APPROVAL


FORM C-AR

OMB Number: ####-####

Estimated average burden hours per response: ##.#

Form C: Filer Information

Filer CIK:
0001139685
Filer CCC:
XXXXXXXX
Period:
01-31-2025


Is this a LIVE or TEST Filing? LIVE TEST
Is this an electronic copy of an official filing submitted in paper format in connection with a hardship exemption?
Would you like a Return Copy?

Submission Contact Information

Name:
Phone Number:
Contact E-Mail Address:
Notify via Filing Website only?

Form C: Issuer Information

Issuer Information

Name of Issuer:
20/20 Biolabs, Inc.


Legal Status of Issuer:

Form:
Corporation


Jurisdiction of Incorporation/Organization:
DELAWARE


Date of Incorporation/Organization:
05-01-2000


Physical Address of Issuer:

Address 1:
15810 GAITHER ROAD, SUITE 235


Address 2:
SUITE 235


City:
GAITHERSBURG


State/Country:
MARYLAND


Mailing Zip/Postal Code:
20877


Website of Issuer:
https://2020biolabs.com/


Form C: Annual Report Disclosure Requirements

Annual Report Disclosure Requirements

Current Number of Employees:
20.00


Total Assets Most Recent Fiscal Year-end:
3584408.00


Total Assets Prior Fiscal Year-end:
6367828.00


Cash and Cash Equivalents Most Recent Fiscal Year-end:
1784009.00


Cash and Cash Equivalents Prior Fiscal Year-end:
4089461.00


Accounts Receivable Most Recent Fiscal Year-end:
135272.00


Accounts Receivable Prior Fiscal Year-end:
68834.00


Short-term Debt Most Recent Fiscal Year-end:
1355078.00


Short-term Debt Prior Fiscal Year-end:
1011623.00


Long-term Debt Most Recent Fiscal Year-end:
723848.00


Long-term Debt Prior Fiscal Year-end:
1068713.00


Revenue/Sales Most Recent Fiscal Year-end:
1752343.00


Revenue/Sales Prior Fiscal Year-end:
1424304.00


Cost of Goods Sold Most Recent Fiscal Year-end:
1373432.00


Cost of Goods Sold Prior Fiscal Year-end:
1315166.00


Taxes Paid Most Recent Fiscal Year-end:
0.00


Taxes Paid Prior Fiscal Year-end:
0.00


Net Income Most Recent Fiscal Year-end:
-5126667.00


Net Income Prior Fiscal Year-end:
-6391309.00


Form C: Signature

Signature

Pursuant to the requirements of Sections 4(a)(6) and 4A of the Securities Act of 1933 and Regulation Crowdfunding (§ 227.100-503), the issuer certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form C and has duly caused this Form to be signed on its behalf by the duly authorized undersigned.
Issuer:
20/20 Biolabs, Inc.


Signature:
Jonathan Cohen


Title:
CEO


Pursuant to the requirements of Sections 4(a)(6) and 4A of the Securities Act of 1933 and Regulation Crowdfunding (§ 227.100-503), this Form C has been signed by the following persons in the capacities and on the dates indicated.

Signature:
Jonathan Cohen


Title:
CEO


Date:
05-20-2025


Pursuant to the requirements of Sections 4(a)(6) and 4A of the Securities Act of 1933 and Regulation Crowdfunding (§ 227.100-503), this Form C has been signed by the following persons in the capacities and on the dates indicated.

Signature:
Jiming Zhou


Title:
COO


Date:
05-20-2025


Pursuant to the requirements of Sections 4(a)(6) and 4A of the Securities Act of 1933 and Regulation Crowdfunding (§ 227.100-503), this Form C has been signed by the following persons in the capacities and on the dates indicated.

Signature:
Ronald R Baker


Title:
Chief Business Officer


Date:
05-20-2025


Pursuant to the requirements of Sections 4(a)(6) and 4A of the Securities Act of 1933 and Regulation Crowdfunding (§ 227.100-503), this Form C has been signed by the following persons in the capacities and on the dates indicated.

Signature:
John W Rollins


Title:
Director


Date:
05-20-2025


Pursuant to the requirements of Sections 4(a)(6) and 4A of the Securities Act of 1933 and Regulation Crowdfunding (§ 227.100-503), this Form C has been signed by the following persons in the capacities and on the dates indicated.

Signature:
Richard M Cohen


Title:
Director


Date:
05-20-2025


Pursuant to the requirements of Sections 4(a)(6) and 4A of the Securities Act of 1933 and Regulation Crowdfunding (§ 227.100-503), this Form C has been signed by the following persons in the capacities and on the dates indicated.

Signature:
Michael S. Lebowitz


Title:
Chief Scientific Officer


Date:
05-20-2025


Pursuant to the requirements of Sections 4(a)(6) and 4A of the Securities Act of 1933 and Regulation Crowdfunding (§ 227.100-503), this Form C has been signed by the following persons in the capacities and on the dates indicated.

Signature:
John G. Compton


Title:
Chair, Board of Directors


Date:
05-20-2025


Pursuant to the requirements of Sections 4(a)(6) and 4A of the Securities Act of 1933 and Regulation Crowdfunding (§ 227.100-503), this Form C has been signed by the following persons in the capacities and on the dates indicated.

Signature:
Michael A. Ross


Title:
Director


Date:
05-20-2025


Pursuant to the requirements of Sections 4(a)(6) and 4A of the Securities Act of 1933 and Regulation Crowdfunding (§ 227.100-503), this Form C has been signed by the following persons in the capacities and on the dates indicated.

Signature:
Prasanth Reddy


Title:
Director


Date:
05-20-2025


Pursuant to the requirements of Sections 4(a)(6) and 4A of the Securities Act of 1933 and Regulation Crowdfunding (§ 227.100-503), this Form C has been signed by the following persons in the capacities and on the dates indicated.

Signature:
Wei Lu


Title:
Director on behalf of Ping An Ventures


Date:
05-20-2025


20/20 Genesystems Inc. published this content on May 20, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on May 20, 2025 at 19:17 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]